SCHEMBL2734875

SCHEMBL2734875

CCCCOC(=O)C(N)Cc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALPI P09923 1/20 0.54
PKM P14618 1/20 0.54
PTGS1 P23219 1/20 0.54
XIAP P98170 1/20 0.54
SLC7A5 Q01650 1/20 0.54
TSHR P16473 3/20 0.52
TDP1 Q9NUW8 2/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
ALDH1A1 P00352 2/20 0.52
CYP3A4 P08684 2/20 0.52
MAPK1 P28482 2/20 0.52
TYR P14679 2/20 0.51
LTA4H P09960 1/20 0.49
HSD17B10 Q99714 1/20 0.48
SLC15A1 P46059 1/20 0.47
DAGLA Q9Y4D2 1/20 0.47
CSNK1E P49674 1/20 0.47
LMNA P02545 1/20 0.45
TP53 P04637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL216480 1.00 ALPI (0.54) ALPIPKMPTGS1XIAPSLC7A5
Hydrochloric Acid SCHEMBL216479 0.98 ALPI (0.53) ALPIPKMPTGS1XIAPSLC7A5
Hydrochloric Acid SCHEMBL5281599 0.98 ALPI (0.53) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL299866 0.95 ALPI (0.53) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL17077436 0.95 ALPI (0.53) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL25200654 0.94 TYR (0.55) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL25180576 0.94 TYR (0.55) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL25180579 0.94 TYR (0.55) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL23859874 0.94 TYR (0.55) ALPIPKMPTGS1XIAPSLC7A5
Hydrochloric Acid SCHEMBL23510785 0.94 TYR (0.52) ALPIPKMPTGS1XIAPSLC7A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105061230-B Method for preparing dapoxetine hydrochloride 康普药业股份有限公司 2017-04-26 CN claimed
CN-102093578-A Preparation method of shape-controllable amino-acid ester (with side group benzene ring) substituted polyphosphazene microspheres UNIV BEIJING CHEMICAL 2011-06-15 CN claimed
WO-2024243289-A2 GUT MICROBE DERIVED AROMATIC AMINO ACID METABOLITES FOR DETECTION AND TREATMENT OF DISEASE THE CLEVELAND CLINIC FOUNDATION (US) 2024-11-28 WO disclosed
EP-4298105-A1 COMPOUNDS USEFUL IN HIV TREATMENT VIIV Healthcare Company (US) 2024-01-03 EP disclosed
EP-2457893-B1 Intermediates for macrocyclic modulators of the ghrelin receptor OCERA THERAPEUTICS INC (US) 2017-08-16 EP disclosed
CN-105061230-B Method for preparing dapoxetine hydrochloride 康普药业股份有限公司 2017-04-26 CN disclosed
US-9493505-B2 Macrocyclic modulators of the ghrelin receptor OCERA THERAPEUTICS, INC. (US) 2016-11-15 US disclosed
US-20150148290-A1 Macrocyclic Modulators of the Ghrelin Receptor MALLINCKRODT LLC 2015-05-28 US disclosed
US-8921521-B2 Macrocyclic modulators of the Ghrelin receptor OCERA THERAPEUTICS, INC. (US) 2014-12-30 US disclosed
US-20130211045-A1 MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR TRANZYME PHARMA INC. (CA) 2013-08-15 US disclosed
US-8455451-B2 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment GILEAD SCIENCES, INC. (US) 2013-06-04 US disclosed
US-20090170757-A1 METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR TRANZYME PHARMA INC. 2009-07-02 US disclosed
US-20090149400-A1 ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. (US) 2009-06-11 US disclosed
US-7491695-B2 Therapy for endocrime disorders; gastrointestinal disorders; cardiovascular disorders; obesity; central nervous system disorders; antiproliferative agents ; using growth hormone secretagogue receptor TRANZYME PHARMA INC. (CA) 2009-02-17 US disclosed
US-7476653-B2 Using growth hormone secretagague receptors; endocrime disorders; gastrointestinal disorders; cardiovascular disorders; central nervous system disorders; antiproliferative agents; antiinflammatory agents TRANZYME PHARMA, INC. (CA) 2009-01-13 US disclosed
CN-101048139-A Compositions for controlled delivery of pharmaceutically active compounds IDEXX LAB INC (US) 2007-10-03 CN disclosed
US-20070021331-A1 Methods of using macrocyclic modulators of the ghrelin receptor TRANZYME PHARMA INC. 2007-01-25 US disclosed
WO-2006009645-A1 METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR TRANZYME PHARMA, INC. (US) 2006-01-26 WO disclosed
EP-0154472-B1 PROCESS FOR THE PRODUCTION OF L-ASPARTYL-L-PHENYLALANINE ESTER AJINOMOTO CO., INC. (JP) 1989-10-11 EP disclosed
EP-0154472-A2 Process for the production of L-aspartyl-L-phenylalanine ester AJINOMOTO CO., INC. (JP) 1985-09-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150148290-A1 Macrocyclic Modulators of the Ghrelin Receptor GHSR, GIPR, GHRHR ALPI 1865/4885PKM 3429/4885PTGS1 691/4885
US-20090170757-A1 METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR GHSR, GHRHR, GIPR ALPI 1494/4885PKM 3654/4885PTGS1 700/4885
US-20130211045-A1 MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR GHSR, GIPR, GHRHR ALPI 1865/4885PKM 3429/4885PTGS1 691/4885
US-20090149400-A1 ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF CCNY, CCNO, CCNB3 ALPI 4221/4885PKM 4594/4885PTGS1 1873/4885
US-20070021331-A1 Methods of using macrocyclic modulators of the ghrelin receptor GHSR, GHRHR, GIPR ALPI 1494/4885PKM 3654/4885PTGS1 700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.